BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Faslodex (Fulvestrant) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Faslodex (Fulvestrant)\, from ClinicalTri
 als.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06663072-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Faslodex (Fulvestrant): Phase 1 readout est. (NCT06663072)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1.\nStudy: Study to Test the Com
 bination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendo
 crine Tumors\nEstimated primary completion: November 2026. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/fulvestrant#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06663072
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07163481-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Faslodex (Fulvestrant): Phase 1 readout est. (NCT07163481)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Trial to Evaluate Sacituzumab Govitecan in Combination W
 ith Endocrine Therapy in Patients With HR-positive\, HER2-negative Metasta
 tic Breast Cancer Progressed on CDK4/6 Inhibitors\nEstimated primary compl
 etion: December 2026. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /fulvestrant#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07163481
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06202261-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Faslodex (Fulvestrant): Phase 1/2 readout est. (NCT06202261)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: A Study of TQB2930 for Injection Monotherapy or Combinat
 ion Therapy in Patients With Recurrent/Metastatic Breast Cancer\nEstimated
  primary completion: December 2026. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/fulvestrant#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06202261
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04115306-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Faslodex (Fulvestrant): Phase 1/2 readout est. (NCT04115306)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: Phase 1/1b/2 Study of Oral PMD-026 in Patients With Meta
 static Breast Cancer\nEstimated primary completion: December 2026. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/fulvestrant#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT04115306
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02738866-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT02738866)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Palbociclib With Fulvestrant for Metastatic Breast Cancer 
 After Treatment With Palbociclib and an Aromatase Inhibitor\nEstimated pri
 mary completion: December 2026. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/fulvestrant#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT02738866
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05305924-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT05305924)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-P
 ositive\, Her2-Negative Metastatic Breast Cancer\nEstimated primary comple
 tion: 1 December 2026. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/fulvestrant#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05305924
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05870579-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Faslodex (Fulvestrant): Phase 1 readout est. (NCT05870579)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestr
 ant in Participants With ER+\, HER2- and GRPR+ Advanced Breast Cancer\nEst
 imated primary completion: 30 December 2026. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/fulvestrant#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05870579
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06239467-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Faslodex (Fulvestrant): Phase 1 readout est. (NCT06239467)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: First-in-Human Study of OKI-219 in Advanced Solid Tumors a
 nd Advanced Breast Cancer\nEstimated primary completion: 31 December 2026.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/fulvestrant#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06239467
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03006172-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Faslodex (Fulvestrant): Phase 1 readout est. (NCT03006172)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: To Evaluate the Safety\, Tolerability\, and Pharmacokineti
 cs of Inavolisib Single Agent in Participants With Solid Tumors and in Com
 bination With Endocrine and Targeted Therapies in Participants With Breast
  Cancer\nEstimated primary completion: 31 December 2026. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/fulvestrant#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT03006172
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02476786-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT02476786)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, Breast Cancer.\nStudy: Endoc
 rine Treatment Alone for Elderly Patients With Estrogen Receptor Positive 
 Operable Breast Cancer and Low Recurrence Score\nEstimated primary complet
 ion: 31 January 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /fulvestrant#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT02476786
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06447623-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Faslodex (Fulvestrant): Phase 3 readout est. (NCT06447623)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Apatinib Combined With cdk4/6i in First-line Treatment for
  HR+/HER2- SNF4 Subtype Breast Cancer\nEstimated primary completion: 1 Feb
 ruary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fulvestra
 nt#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6447623
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06208410-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:Faslodex (Fulvestrant): Phase 1/2 readout est. (NCT06208410)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1/2.\nStudy: A Clinical Study of
  JS105 in Combination With Other Anti-tumor Therapies in Patients With Sol
 id Tumors\nEstimated primary completion: 26 February 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/fulvestrant#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06208410
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04524000-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT04524000)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Study Assessing the Efficacy and Safety of Treatment With 
 Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With A
 dvanced Breast Cancer\nEstimated primary completion: 26 February 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/fulvestrant#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT04524000
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06179303-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT06179303)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Functional Imaging in Prediction of Response to Abemacicli
 b for Advanced Hormone Receptor-Positive\, HER2-Negative Breast Cancer\nEs
 timated primary completion: 1 March 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/fulvestrant#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06179303
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT00585507-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20270315
DTEND;VALUE=DATE:20270316
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT00585507)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Efficacy and Safety of 500mg of Fulvestrant\nEstimated pri
 mary completion: 15 March 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/fulvestrant#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT00585507
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07923214-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Faslodex (Fulvestrant): Phase 1 readout est. (NCT07923214)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Phase I Dose Escalation Study of CG-7321 Monotherapy or 
 Combination Therapy in Advanced Solid Tumors\nEstimated primary completion
 : April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fulvest
 rant#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07923214
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06736704-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Faslodex (Fulvestrant): Phase 1/2 readout est. (NCT06736704)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1/2.\nStudy: SNV4818 in Particip
 ants With Advanced Solid Tumors\nEstimated primary completion: April 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/fulvestrant#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06736704
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06409390-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT06409390)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Sequential Therapies Modeled on Evolutionary Dynamics for 
 Breast Cancer\nEstimated primary completion: April 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/fulvestrant#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06409390
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07426822-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT07426822)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Rash & Diarrhea Prophylaxis With Capivasertib\nEstimated p
 rimary completion: April 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/fulvestrant#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07426822
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06506955-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Faslodex (Fulvestrant): Phase 2/3 readout est. (NCT06506955)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2/3.\nStudy: Futibatinib in Pati
 ents Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Co
 mbination Therapy.\nEstimated primary completion: April 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/fulvestrant#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06506955
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05986071-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Faslodex (Fulvestrant): Phase 1/2 readout est. (NCT05986071)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: I/II Phase Study Evaluating M1774 in Combination With Fu
 lvestrant in HR+ and HER2- Advanced Breast Cancers\nEstimated primary comp
 letion: 1 April 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /fulvestrant#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05986071
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05319873-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Faslodex (Fulvestrant): Phase 1/2 readout est. (NCT05319873)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1/2\, Breast Cancer.\nStudy: Rib
 ociclib\, Tucatinib\, and Trastuzumab for the Treatment of HER2 Positive B
 reast Cancer\nEstimated primary completion: 1 April 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/fulvestrant#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05319873
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01953588-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Faslodex (Fulvestrant): Phase 3 readout est. (NCT01953588)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 3\, Breast Cancer.\nStudy: Fulve
 strant and/or Anastrozole in Treating Postmenopausal Patients With Stage I
 I-III Breast Cancer Undergoing Surgery\nEstimated primary completion: 1 Ap
 ril 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fulvestrant
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT019
 53588
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07358377-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20270410
DTEND;VALUE=DATE:20270411
SUMMARY:Faslodex (Fulvestrant): Phase 1 readout est. (NCT07358377)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Trial of HRS-6209-205 to Evaluate the Safety\, Tolerabil
 ity\, Pharmacokinetics and Efficacy of HRS-6209 in Combination Therapy in 
 Subjects With HR-Positive/HER2-Negative Cancer\nEstimated primary completi
 on: 10 April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fu
 lvestrant#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07358377
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05216432-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Faslodex (Fulvestrant): Phase 1 readout est. (NCT05216432)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: First-in-Human Study of Mutant-selective PI3Kα Inhibitor\
 , RLY-2608\, as a Single Agent in Patients With Advanced Solid Tumors and 
 in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Pa
 tients With Advanced Solid Tumors or Advanced Breast Cancer\nEstimated pri
 mary completion: 30 April 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/fulvestrant#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05216432
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06428396-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20270505
DTEND;VALUE=DATE:20270506
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT06428396)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER
 2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)\nEstimated primary
  completion: 5 May 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/fulvestrant#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06428396
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06784193-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20270530
DTEND;VALUE=DATE:20270531
SUMMARY:Faslodex (Fulvestrant): Phase 1 readout est. (NCT06784193)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Phase 1 Study of OP-3136 in Advanced or Metastatic Solid T
 umors\nEstimated primary completion: 30 May 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/fulvestrant#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06784193
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04920708-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT04920708)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Fulvestrant\, Ipatasertib and CDK4/6 Inhibition in Metasta
 tic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression\nEstimated 
 primary completion: June 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/fulvestrant#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT04920708
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07117630-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT07117630)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: An Open-Label\, Bayesian Adaptive Phase II Clinical Study 
 in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy\
 nEstimated primary completion: June 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/fulvestrant#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07117630
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07557004-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Faslodex (Fulvestrant): Phase 1 readout est. (NCT07557004)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Study of SH3765 Tablets in Combination With Fulvestrant 
 in Patients With HR+/HER2- Advanced Breast Cancer.\nEstimated primary comp
 letion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /fulvestrant#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07557004
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06993844-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Faslodex (Fulvestrant): Phase 1/2 readout est. (NCT06993844)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: Phase 1/2 Study of ETX-636 in Participants With Advanced
  Solid Tumors\nEstimated primary completion: 30 June 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/fulvestrant#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06993844
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07498478-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT07498478)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Efficacy and Safety of Tinengotinib Tablets Combined With 
 Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recu
 rrent or Metastatic Breast Cancer Who Have Failed Prior Treatment\nEstimat
 ed primary completion: 30 June 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/fulvestrant#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07498478
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05735080-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Faslodex (Fulvestrant): Phase 1/2 readout est. (NCT05735080)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: Open-Label Study to Evaluate the Safety\, Tolerability\,
  PK\, and Efficacy of INX-315 in Patients With Advanced Cancer\nEstimated 
 primary completion: July 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/fulvestrant#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05735080
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07062965-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20270722
DTEND;VALUE=DATE:20270723
SUMMARY:Faslodex (Fulvestrant): Phase 3 readout est. (NCT07062965)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Study to Learn About the Study Medicine Called PF-072481
 44 in Combination With Fulvestrant in People With HR-positive\, HER2-negat
 ive Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line
  of Treatment.\nEstimated primary completion: 22 July 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/fulvestrant#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07062965
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05238922-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20270727
DTEND;VALUE=DATE:20270728
SUMMARY:Faslodex (Fulvestrant): Phase 1 readout est. (NCT05238922)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1.\nStudy: Study of INCB123667 i
 n Subjects With Advanced Solid Tumors\nEstimated primary completion: 27 Ju
 ly 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/fulvestrant#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0523
 8922
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06756932-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Faslodex (Fulvestrant): Phase 1 readout est. (NCT06756932)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With H
 ormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Ne
 gative (HER2-) Metastatic Breast Cancer\nEstimated primary completion: 30 
 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fulvestran
 t#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 756932
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07029399-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Faslodex (Fulvestrant): Phase 1 readout est. (NCT07029399)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Study With NKT5097 for Adults With Advanced/Metastatic S
 olid Tumors\nEstimated primary completion: 31 July 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/fulvestrant#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07029399
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06494150-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT06494150)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2.\nStudy: Nab-Sirolimus and End
 ocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO)\nEsti
 mated primary completion: August 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/fulvestrant#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06494150
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07180160-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT07180160)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-
 positive\, HER2-negative Advanced Breast Cancer\nEstimated primary complet
 ion: September 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 fulvestrant#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07180160
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04985266-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT04985266)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Trial of Early Detection of Molecular Relapse With Circu
 lating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant
  Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negat
 ive Breast Cancer\nEstimated primary completion: 1 September 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/fulvestrant#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT04985266
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06515470-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Faslodex (Fulvestrant): Phase 1 readout est. (NCT06515470)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Safety\, Tolerability\, Pharmacokinetics\, and Preliminary
  Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer\nEstimat
 ed primary completion: 30 September 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/fulvestrant#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06515470
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03531645-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT03531645)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2.\nStudy: Fulvestrant Plus Abem
 aciclib in Women With Advanced Low Grade Serous Carcinoma\nEstimated prima
 ry completion: 30 September 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/fulvestrant#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT03531645
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06941142-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Faslodex (Fulvestrant): Phase 1 readout est. (NCT06941142)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Study of Sirolimus (Albumin-Bound) in Combination With P
 albociclib and Fulvestrant for the Treatment of Advanced Breast Cancer\nEs
 timated primary completion: October 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/fulvestrant#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06941142
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05090358-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20271008
DTEND;VALUE=DATE:20271009
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT05090358)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Preventing High Blood Sugar in People Being Treated for Me
 tastatic Breast Cancer\nEstimated primary completion: 8 October 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/fulvestrant#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05090358
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06612814-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Faslodex (Fulvestrant): Phase 3 readout est. (NCT06612814)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therap
 y in HR+/ HER2-Advanced Breast Cancer\nEstimated primary completion: 30 Oc
 tober 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fulvestra
 nt#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6612814
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06110793-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Faslodex (Fulvestrant): Phase 1/2 readout est. (NCT06110793)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: A Study of Lenvatinib\, Pembrolizumab\, and Fulvestrant 
 in People With Breast Cancer\nEstimated primary completion: November 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/fulvestrant#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06110793
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06979596-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20271104
DTEND;VALUE=DATE:20271105
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT06979596)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2.\nStudy: A Study of MK-5684 in
  People With Certain Solid Tumors (MK-5684-015/OMAHA-015)\nEstimated prima
 ry completion: 4 November 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/fulvestrant#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06979596
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07333937-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20271120
DTEND;VALUE=DATE:20271121
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT07333937)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, Breast Cancer.\nStudy: Nerat
 inib Combined With Fulvestrant and Eribulin in the Treatment ofHR+/HER2+ A
 dvanced Breast Cancer\nEstimated primary completion: 20 November 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/fulvestrant#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07333937
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07330544-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20271125
DTEND;VALUE=DATE:20271126
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT07330544)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Phase II Clinical Study Evaluating Entinostat With or Wi
 thout Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -
 Positive\, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Adva
 nced Breast Cancer That Relapsed or Progressed After Endocrine Therapy\nEs
 timated primary completion: 25 November 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/fulvestrant#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07330544
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05826964-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT05826964)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Levels of Circulating Tumor DNA as a Predictive Marker for
  Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast 
 Cancer\nEstimated primary completion: 30 November 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/fulvestrant#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT05826964
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06764186-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Faslodex (Fulvestrant): Phase 3 readout est. (NCT06764186)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Phase IIIB Study to Evaluate the Use of Capivasertib in 
 Combination With Fulvestrant in Patients With Advanced Breast Cancer Who H
 ave Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World C
 linical Practice in Spain\nEstimated primary completion: 30 November 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/fulvestrant#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06764186
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05683418-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Faslodex (Fulvestrant): Phase 1 readout est. (NCT05683418)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Study to Evaluate the Safety and Tolerability of TOS-358
  in Women With HR+ HER2- Breast Cancer\nEstimated primary completion: Dece
 mber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fulvestran
 t#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 683418
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06555068-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Faslodex (Fulvestrant): Phase 1/2 readout est. (NCT06555068)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: A Trial of HRS-6209 in Combination With Other Antitumor 
 Therapies in Breast Cancer Patients or HRS-9813 as Monotherapy in Patients
  With Advanced Solid Tumors\nEstimated primary completion: December 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/fulvestrant#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06555068
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227233-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT07227233)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Artificial Intelligence and Machine Learning to Guide CDK4
 /6 Inhibitor Rechallenge in Breast Cancer.\nEstimated primary completion: 
 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fulves
 trant#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07227233
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05608252-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Faslodex (Fulvestrant): Phase 1/2 readout est. (NCT05608252)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: VS-6766+Abema+Fulv in Met HR+/HER- BC\nEstimated primary
  completion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/fulvestrant#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05608252
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05601440-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT05601440)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-i
 nhibitor Resistant ER+/HER2- Metastatic Breast Cancer\nEstimated primary c
 ompletion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/fulvestrant#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05601440
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04567420-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT04567420)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, Breast Cancer.\nStudy: DNA-g
 uided Second Line Adjuvant Therapy for High Residual Risk\, Estrogen Recep
 tor Positive\, HER-2 Negative Breast Cancer (DARE)\nEstimated primary comp
 letion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/fulvestrant#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT04567420
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07235618-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT07235618)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Study of Entinostat in Combination With Fulvestrant for 
 the Treatment of Locally Advanced or Metastatic Breast Cancer\nEstimated p
 rimary completion: January 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/fulvestrant#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07235618
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05328440-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT05328440)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, Breast Cancer.\nStudy: Treat
 ment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2
 + Advanced Breast Cancer(DAP-Her-02)\nEstimated primary completion: 1 Janu
 ary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fulvestrant
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT053
 28440
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05867251-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Faslodex (Fulvestrant): Phase 1/2 readout est. (NCT05867251)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: Study of AVZO-021 in Patients With Advanced Solid Tumors
 \nEstimated primary completion: 31 January 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/fulvestrant#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05867251
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07287917-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Faslodex (Fulvestrant): Phase 1/2 readout est. (NCT07287917)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: Study of AMXT 1501 and DFMO in Combination With Standard
  Therapies in Advanced Solid Tumors\nEstimated primary completion: 28 Febr
 uary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fulvestran
 t#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 287917
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07480681-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Faslodex (Fulvestrant): Phase 1 readout est. (NCT07480681)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1.\nStudy: Phase I Clinical Stud
 y to Evaluate the Safety\, Tolerability\, Pharmacokinetics\, and Prelimina
 ry Efficacy of HLX97 (a KAT6A/B Inhibitor) in Patients With Advanced/Metas
 tatic Solid Tumor\nEstimated primary completion: March 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/fulvestrant#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07480681
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06788197-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Faslodex (Fulvestrant): Phase 1/2 readout est. (NCT06788197)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: A Study of SHR-A1811 and Fulvestrant\, With or Without H
 S-10352\, in Locally Advanced or Metastatic Breast Cancer Patients\nEstima
 ted primary completion: 31 March 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/fulvestrant#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06788197
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06982521-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Faslodex (Fulvestrant): Phase 3 readout est. (NCT06982521)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + 
 Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant 
 HR+/HER2- Breast Cancer\nEstimated primary completion: 30 April 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/fulvestrant#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06982521
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05154487-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20280501
DTEND;VALUE=DATE:20280502
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT05154487)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2.\nStudy: A Study of Alpelisib 
 and Fulvestrant to Treat Endometrial Cancer\nEstimated primary completion:
  1 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fulvestr
 ant#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05154487
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07857226-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT07857226)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, Breast Cancer.\nStudy: Trast
 uzumab/Pertuzumab With Fulvestrant and Culmerciclib in HR+/HER2+ Early Bre
 ast Cancer\nEstimated primary completion: June 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/fulvestrant#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07857226
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07666555-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT07666555)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Phase II Clinical Study of the Efficacy and Safety of Cu
 lmerciclib Rechallenge in HR-positive\, HER2-negative Breast Cancer Patien
 ts With Resistance to First-line Endocrine Therapy.\nEstimated primary com
 pletion: 30 June 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/fulvestrant#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07666555
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07604272-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Faslodex (Fulvestrant): Phase 1 readout est. (NCT07604272)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1.\nStudy: Reversing InGuinal He
 rnia Trial: The Evaluation of Sex Hormones to Reverse Inguinal Hernias in 
 Males\nEstimated primary completion: July 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/fulvestrant#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07604272
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06145308-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20280710
DTEND;VALUE=DATE:20280711
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT06145308)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2.\nStudy: Precision Treatment o
 f Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
 \nEstimated primary completion: 10 July 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/fulvestrant#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06145308
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06998407-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Faslodex (Fulvestrant): Phase 1/2 readout est. (NCT06998407)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: ORION-1: Study of AVZO-023 as a Single Agent and in Comb
 ination With AVZO-021\, and/or Endocrine Therapy in Advanced Solid Tumors\
 nEstimated primary completion: August 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/fulvestrant#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06998407
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05467891-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20280815
DTEND;VALUE=DATE:20280816
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT05467891)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Ribociclib And Endocrine Treatment of Physician's Choice f
 or Locoregional Recurrent\, Resected Hormone Receptor Positive HER2 Negati
 ve Breast Cancer\nEstimated primary completion: 15 August 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/fulvestrant#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT05467891
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07038369-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Faslodex (Fulvestrant): Phase 1 readout est. (NCT07038369)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Phase 1 Study of ATV-1601 in Patients With Advanced Canc
 er That Have AKT1 E17K Mutations\nEstimated primary completion: 31 August 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/fulvestrant#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0703836
 9
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07861932-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Faslodex (Fulvestrant): Phase 1/2 readout est. (NCT07861932)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: A Phase 1/2a Study of K-1728 in Advanced Solid Tumors\nE
 stimated primary completion: September 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/fulvestrant#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07861932
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06726148-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20280925
DTEND;VALUE=DATE:20280926
SUMMARY:Faslodex (Fulvestrant): Phase 1/2 readout est. (NCT06726148)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: Study of ECI830 Single Agent or in Combination in Patien
 ts With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanc
 ed Solid Tumors\nEstimated primary completion: 25 September 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/fulvestrant#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06726148
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07619066-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20280928
DTEND;VALUE=DATE:20280929
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT07619066)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Phase II Study of Zongertinib Plus Fulvestrant in Partic
 ipants With HR-positive/HER2-negative Advanced Breast Cancer Harboring HER
 2 Mutations.\nEstimated primary completion: 28 September 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/fulvestrant#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07619066
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07905001-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Faslodex (Fulvestrant): Phase 1 readout est. (NCT07905001)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Phase 1/1b Study of PRT13722 in Participants With Advanc
 ed HR+/HER2- Breast Cancer\nEstimated primary completion: 31 October 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/fulvestrant#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07905001
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07368998-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT07368998)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: To Study the Effect of Inavolisib in Combination With Fulv
 estrant in Participants With Breast Cancer\nEstimated primary completion: 
 31 October 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fulv
 estrant#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07368998
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06625775-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Faslodex (Fulvestrant): Phase 1 readout est. (NCT06625775)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Open-Label Study of BBO-10203 in Subjects With Advanced So
 lid Tumors\nEstimated primary completion: November 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/fulvestrant#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06625775
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07226349-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20281101
DTEND;VALUE=DATE:20281102
SUMMARY:Faslodex (Fulvestrant): Phase 1 readout est. (NCT07226349)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1.\nStudy: A Study of BG-75098 A
 lone and in Combination With Other Agents in Adults With Advanced Solid Tu
 mors\nEstimated primary completion: 1 November 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/fulvestrant#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07226349
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07340619-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20281118
DTEND;VALUE=DATE:20281119
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT07340619)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Clinical Trial Evaluating the Biological Activity of a New
  Drug Identified as Prifetrastat (PF-07248144)\, Combined With Fulvestrant
  for the Treatment of Patients With Hormone Receptor Positive (HR+) and HE
 R2 Negative (HER2-) Breast Cancer Extended to Other Organs.\nEstimated pri
 mary completion: 18 November 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/fulvestrant#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07340619
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07784036-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Faslodex (Fulvestrant): Phase 3 readout est. (NCT07784036)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: JYP0035 Capsules Plus Fulvestrant in PIK3CA-Mutant HR+/HER
 2- Advanced Breast Cancer\nEstimated primary completion: 30 November 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/fulvestrant#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07784036
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07389733-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Faslodex (Fulvestrant): Phase 1/2 readout est. (NCT07389733)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: A Study of HRS-6208 in Combination With HRS-8080\, or Fu
 lvestrant\, or Letrozole\, With or Without HRS-6209 in Patients With Advan
 ced Unresectable or Metastatic Breast Cancer\nEstimated primary completion
 : December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fulv
 estrant#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07389733
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07618390-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT07618390)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Phase ll\, Interventional\, Single-arm Study Evaluating 
 the Efficacy and Safety of Inavolisib Plus Ribociclib and Fulvestrant in C
 hinese Patients With PIK3CA-mutant\, HR-positive\, HER2-negative Locally A
 dvanced or Metastatic Breast Cancer.\nEstimated primary completion: Decemb
 er 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/fulvestrant#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0761
 8390
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06997029-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20281214
DTEND;VALUE=DATE:20281215
SUMMARY:Faslodex (Fulvestrant): Phase 1 readout est. (NCT06997029)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Phase 1 Study of BMS-986500 as Monotherapy or Combinatio
 n Therapy in Advanced Solid Tumors\nEstimated primary completion: 14 Decem
 ber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fulvestrant
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT069
 97029
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04646759-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20281214
DTEND;VALUE=DATE:20281215
SUMMARY:Faslodex (Fulvestrant): Phase 3 readout est. (NCT04646759)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Fulvestrant or Capecitabine Combined With Pyrotinib in HR+
 /HER2+ Metastatic Breast Cancer\nEstimated primary completion: 14 December
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/fulvestrant#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT046467
 59
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07109726-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Faslodex (Fulvestrant): Phase 1/2 readout est. (NCT07109726)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: A Phase 1/2 Trial of TER-2013 in Patients With Solid Tum
 ors Harboring AKT/PI3K/PTEN Pathway Alterations\nEstimated primary complet
 ion: 30 December 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/fulvestrant#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07109726
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05816655-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT05816655)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Comparison of Clinical Efficacy Between Letrozole + Riboci
 clib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive
 \, HER2 Negative Metastatic Breast Cancer\nEstimated primary completion: 3
 1 December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fulv
 estrant#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05816655
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05524584-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT05524584)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Anastrazole\, Fulvestrant & Abemaciclib for HR+HER2- Metas
 tatic Breast Cancer\nEstimated primary completion: 31 December 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/fulvestrant#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05524584
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07944092-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Faslodex (Fulvestrant): Phase 1/2 readout est. (NCT07944092)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1/2.\nStudy: Ph 1/2 Study to Eva
 luate Safety & Tolerability of FMC-242 Alone and in Combination in Adults 
 With Advanced Solid Tumors\nEstimated primary completion: January 2029. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/fulvestrant#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07944092
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07787520-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Faslodex (Fulvestrant): Phase 1 readout est. (NCT07787520)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1.\nStudy: A Study of LAE118 as 
 Monotherapy and in Combination With Antitumor Agents in Advanced Solid Tum
 ors\nEstimated primary completion: March 2029. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/fulvestrant#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07787520
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05394103-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Faslodex (Fulvestrant): Phase 1/2 readout est. (NCT05394103)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1/2.\nStudy: Highly Selective CD
 K7 Inhibitor Q901 in Selected Advanced Solid Tumors\nEstimated primary com
 pletion: 31 March 2029. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/fulvestrant#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT05394103
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06757634-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Faslodex (Fulvestrant): Phase 3 readout est. (NCT06757634)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Phase 3 Study of Gedatolisib as First-Line Treatment for P
 atients With HR-Positive\, HER2-Negative Advanced Breast Cancer (VIKTORIA-
 2)\nEstimated primary completion: 31 March 2029. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/fulvestrant#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06757634
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05362760-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Faslodex (Fulvestrant): Phase 4 readout est. (NCT05362760)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 4\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Combination of Abemaciclib and Endocrine Therapy in Hormon
 e Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Ca
 ncer With Focus on Digital Side Effect Management\nEstimated primary compl
 etion: April 2029. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fu
 lvestrant#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT05362760
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07318805-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20290414
DTEND;VALUE=DATE:20290415
SUMMARY:Faslodex (Fulvestrant): Phase 1 readout est. (NCT07318805)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Study to Learn About the Study Medicine Called PF-080325
 62 in People With Advanced or Metastatic Solid Tumors\nEstimated primary c
 ompletion: 14 April 2029. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/fulvestrant#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07318805
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07558733-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Faslodex (Fulvestrant): Phase 1/2 readout est. (NCT07558733)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: Sapanisertib and Serabelisib (PIKTOR) in Various Combina
 tions in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer\nEstima
 ted primary completion: May 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/fulvestrant#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07558733
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07207070-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Faslodex (Fulvestrant): Phase 3 readout est. (NCT07207070)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Randomised\, Open-label\, Multicentre Phase III Clinical
  Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpicic
 lib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients 
 With PIK3CA-mutated\, HR-positive\, HER2-negative Recurrent or Metastatic 
 Breast Cancer.\nEstimated primary completion: 31 May 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/fulvestrant#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07207070
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07748208-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20290615
DTEND;VALUE=DATE:20290616
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT07748208)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Study Evaluating the Safety of Inavolisib and Fulvestran
 t With or Without Palbociclib in Participants With Advanced Breast Cancer 
 (ABC) and Type 2 Diabetes\nEstimated primary completion: 15 June 2029. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/fulvestrant#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07748208
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04606446-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20290827
DTEND;VALUE=DATE:20290828
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT04606446)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Study of PF-07248144 in Advanced or Metastatic Solid Tumor
 s\nEstimated primary completion: 27 August 2029. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/fulvestrant#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT04606446
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04557449-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20291007
DTEND;VALUE=DATE:20291008
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT04557449)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Study to Test the Safety and Tolerability of PF-07220060 i
 n Participants With Advance Solid Tumors\nEstimated primary completion: 7 
 October 2029. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fulvest
 rant#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T04557449
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07767474-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20291028
DTEND;VALUE=DATE:20291029
SUMMARY:Faslodex (Fulvestrant): Phase 1/2 readout est. (NCT07767474)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1/2.\nStudy: A Study to Evaluate
  ATX-898 in Participants With Advanced Solid Tumors\nEstimated primary com
 pletion: 28 October 2029. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/fulvestrant#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07767474
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07937605-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT07937605)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: KC1086 in Combination With Fulvestrant for HR-Positive\, H
 ER2-Negative Advanced Breast Cancer\nEstimated primary completion: Novembe
 r 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/fulvestrant#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07937
 605
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06120283-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Faslodex (Fulvestrant): Phase 1 readout est. (NCT06120283)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: BGB-43395 Alone or as Part of Combination Therapies in Par
 ticipants With Breast Cancer and Other Advanced Solid Tumors\nEstimated pr
 imary completion: December 2029. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/fulvestrant#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06120283
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06380751-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20291218
DTEND;VALUE=DATE:20291219
SUMMARY:Faslodex (Fulvestrant): Phase 3 readout est. (NCT06380751)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Th
 erapy\, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Cami
 zestrant in HR-Positive\, HER2-Negative (IHC 0\, 1+\, 2+/ ISH Non-amplifie
 d)\, BRCA1\, BRCA2\, or PALB2m Advanced Breast Cancer\nEstimated primary c
 ompletion: 18 December 2029. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/fulvestrant#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06380751
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07540572-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Faslodex (Fulvestrant): Phase 1 readout est. (NCT07540572)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1.\nStudy: A Study to Investigat
 e the Safety\, Pharmacokinetics\, and Preliminary Efficacy of IDE574 Thera
 py in Adult Participants With Advanced Solid Tumors\nEstimated primary com
 pletion: 31 December 2029. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/fulvestrant#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07540572
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05226871-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT05226871)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Study for Participants Continuing From Pfizer-sponsored Pa
 lbociclib (a Study Medicine) Studies\nEstimated primary completion: 31 Dec
 ember 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fulvestra
 nt#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5226871
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07897721-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20300322
DTEND;VALUE=DATE:20300323
SUMMARY:Faslodex (Fulvestrant): Phase 1 readout est. (NCT07897721)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Study to Learn About the Study Medicine Called PF-081657
 84 in People With PIK3CA-Mutated Advanced or Metastatic Solid Tumors\nEsti
 mated primary completion: 22 March 2030. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/fulvestrant#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07897721
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05161195-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20300628
DTEND;VALUE=DATE:20300629
SUMMARY:Faslodex (Fulvestrant): Phase 4 readout est. (NCT05161195)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 4\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Roll-over Study to Allow Continued Access to Ribociclib\nE
 stimated primary completion: 28 June 2030. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/fulvestrant#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05161195
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05768139-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Faslodex (Fulvestrant): Phase 1/2 readout est. (NCT05768139)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: First-in-Human Study of Tersolisib (STX-478) as Monother
 apy and in Combination With Other Antineoplastic Agents in Participants Wi
 th Advanced Solid Tumors\nEstimated primary completion: July 2030. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/fulvestrant#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05768139
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05564377-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20300701
DTEND;VALUE=DATE:20300702
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT05564377)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Targeted Therapy Directed by Genetic Testing in Treating P
 atients With Locally Advanced or Advanced Solid Tumors\, The ComboMATCH Sc
 reening Trial\nEstimated primary completion: 1 July 2030. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/fulvestrant#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05564377
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07867262-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20300815
DTEND;VALUE=DATE:20300816
SUMMARY:Faslodex (Fulvestrant): Phase 1 readout est. (NCT07867262)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Study to Evaluate the Effects of GDC-4198 in Combination
  With Letrozole\, Fulvestrant\, or Giredestrant in Participants With Local
 ly Advanced or Metastatic Hormone Receptor-Positive\, HER2-Negatve Breast 
 Cancer\nEstimated primary completion: 15 August 2030. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/fulvestrant#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07867262
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07716046-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20300831
DTEND;VALUE=DATE:20300901
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT07716046)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Fulvestaciclib Combined With Anti-HER2 and Endocrine Thera
 py for HR+/HER2+ Advanced Breast Cancer\nEstimated primary completion: 31 
 August 2030. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fulvestr
 ant#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07716046
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07811232-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20300901
DTEND;VALUE=DATE:20300902
SUMMARY:Faslodex (Fulvestrant): Phase 1/2 readout est. (NCT07811232)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: A Study of AL58805 in Advanced\, Metastatic GYN\, STS or
  Breast Cancers\nEstimated primary completion: 1 September 2030. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/fulvestrant#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07811232
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03424005-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Faslodex (Fulvestrant): Phase 1/2 readout est. (NCT03424005)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: A Study Evaluating the Efficacy and Safety of Multiple T
 reatment Combinations in Patients With Metastatic or Locally Advanced Brea
 st Cancer\nEstimated primary completion: 30 September 2030. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/fulvestrant#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT03424005
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05933395-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT05933395)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Genetically-informed Therapy for ER+ Breast Cancer Post-CD
 K4/6 Inhibitor\nEstimated primary completion: October 2030. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/fulvestrant#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05933395
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07892274-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Faslodex (Fulvestrant): Phase 3 readout est. (NCT07892274)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Trastuzumab Rezetecan Followed by Pyrotinib\, Fulvestrant\
 , and Dalpiciclib in HR-Positive\, HER2-Positive Advanced Breast Cancer\nE
 stimated primary completion: 31 December 2030. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/fulvestrant#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07892274
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07288359-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20310509
DTEND;VALUE=DATE:20310510
SUMMARY:Faslodex (Fulvestrant): Phase 1/2 readout est. (NCT07288359)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: Study of GVV858 as a Single Agent or in Combination With
  Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Adva
 nced Solid Tumors\nEstimated primary completion: 9 May 2031. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/fulvestrant#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07288359
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06849947-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20310630
DTEND;VALUE=DATE:20310701
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT06849947)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Fulvestrant With Ribociclib Versus Physician's Choice Trea
 tments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 I
 nhibitors in HR+\, HER2- Metastatic Breast Cancer\nEstimated primary compl
 etion: 30 June 2031. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 fulvestrant#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06849947
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07679269-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20320323
DTEND;VALUE=DATE:20320324
SUMMARY:Faslodex (Fulvestrant): Phase 2 readout est. (NCT07679269)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Roll-Over Study of Alpelisib (BYL719) for Continued Access
  and Long-Term Safety.\nEstimated primary completion: 23 March 2032. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/fulvestrant#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07679269
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07604571-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20320608
DTEND;VALUE=DATE:20320609
SUMMARY:Faslodex (Fulvestrant): Phase 1 readout est. (NCT07604571)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 1\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Study of IEV407 as Single Agent or in Combination in Patie
 nts With Advanced HR+/HER2- Breast Cancer\nEstimated primary completion: 8
  June 2032. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fulvestra
 nt#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7604571
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07802626-9030@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20341030
DTEND;VALUE=DATE:20341031
SUMMARY:Faslodex (Fulvestrant): Phase 3 readout est. (NCT07802626)
DESCRIPTION:Faslodex (Fulvestrant)\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Adding Capivasertib to Standard Treatment in HR Positive\,
  HER2 Negative Metastatic Breast Cancer Based on ctDNA Testing\nEstimated 
 primary completion: 30 October 2034. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/fulvestrant#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07802626
URL:https://assetmemo.bio/drug/fulvestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
